Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

I4. New vaccines

Poster Session: New Vaccines

(P-597) Amezosvatein Demonstrates Non-Inferior Immunogenicity and Superior Tolerability Head-to-Head vs Shingrix in a Phase 2 Herpes Zoster Vaccine Trial

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
Location: Halls JK

    Co-Author(s)

  • LS

    Lisa R. Shelton, ARNP

    Sr. Director, Clinical Development
    Curevo Vaccine
    Bothell, Washington, United States

  • JY

    Jon Yankey, MS

    Principal Biostatistician
    Curevo Vaccine, Veristat Inc.
    Bothell, Washington, United States

  • SG

    Soren Gantt, MD PHD MPH FRCPC

    Professeur de Microbiologiem, infectiologie et immunologie et de Pédiatrie
    Université de Montréal
    Montreal, Quebec, Canada

    • Presenting Author(s)

  • Guy De La Rosa, MD

    Chief Medical Officer
    Curevo Vaccine
    Bothell, Washington, United States

    • Co-Author(s)

  • DS

    David A. G. Skibinski, PhD

    Director, Immunology
    Curevo Vaccine
    Bothell, Washington, United States

  • GS

    George Simeon, MPH

    CEO
    Curevo Inc.
    Bothell, Washington, United States

  • DM

    David Miller, BA

    Sr. Director, Strategic Communications
    Curevo Vaccine
    Bothell, Washington, United States